Which Is the Bigger Story for BioNTech -- Its Colorectal Cancer Vaccine Setback or the Lung Cancer Clinical Success?
The company is looking to prove it can achieve significant success outside the coronavirus market.
BioNTech's stock experienced a significant jolt following a major clinical trial win from Moderna, a fellow mRNA-based vaccine specialist. However, the company's own progress in clinical trials has been mixed. Two recent developments stand out: a setback in the Phase 2 clinical trial for an mRNA-based personalized cancer vaccine for colorectal cancer, and a notable success in lung cancer treatment.
The Phase 2 results led to the termination of the trial, with an independent committee concluding that further treatment would not impact efficacy and noting a disparity in overall survival between the treatment groups. This setback raises questions about BioNTech's future in colorectal cancer vaccine development. On the other hand, the company's lung cancer clinical success has injected optimism into its stock.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
